Nitrogen In R Patents (Class 514/626)
  • Patent number: 9999601
    Abstract: The presently claimed and disclosed invention(s) provides a therapeutically effective composition and method of inhibiting nerve cell transmission. In a preferred embodiment of the presently claimed and disclosed invention(s), the treatment of neuropathic pain utilizing terpene compounds isolated from plant essential oils or manufactured synthetically is detailed. These compounds, such as geraniol and citronellol, as well as chemical analogs thereof, used in combination or individually, can be used alone or in a composition with a pharmaceutically acceptable carrier in a suitable dosage form.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: June 19, 2018
    Assignee: NEUROQUEST INC.
    Inventors: Alexander McLellan, Frank Greenway
  • Patent number: 9907739
    Abstract: The present invention relates to a crosslinked hyaluronic acid gel which derives from the crosslinking of hyaluronic acid or of a salt thereof in the presence of at least an effective amount of at least one endogenous polyamine as a crosslinking agent, said crosslinking being carried out under conditions favourable to the coupling of said hyaluronic acid and of said endogenous polyamine(s).
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: March 6, 2018
    Assignee: TEOXANE
    Inventors: François Bourdon, Stéphane Meunier
  • Patent number: 9907808
    Abstract: An inventive composition including an amount of sugar or sugar alcohol, an amount of alkalizing agent, and an amount of vehicle; whereby the inventive composition is formulated for transdermal administration to alleviate one or more disorder symptoms, for example neurogenic pain, or to treat one or more disorders, for example neurogenic inflammation.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: March 6, 2018
    Assignee: Nova Neura, LLC
    Inventors: David George, Stuart Fife, Howard Rosen
  • Patent number: 9877972
    Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?, 7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?, 7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?, 7?,17?-triol and uses of such formulations in treating the described conditions.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: January 30, 2018
    Assignee: NeurMedix, Inc.
    Inventors: Steven K White, Igor Ivanisevic, Kyle Stephens, Mark Andres, Brenton Skylar Wolfe
  • Patent number: 9849102
    Abstract: A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50% or more while not affecting a corresponding TNF-? related activity level by more than 30% comprises providing a pharmaceutical composition comprising a local anaesthetic, in particular lidocaine hydrochloride, and a pharmaceutically acceptable carrier, administering the composition intraperitoneally to said person, thereby substantially reducing the recruitment of macrophages by MCP-1 released from the endometriosis implant. Also disclosed is a corresponding pharmaceutical composition.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: December 26, 2017
    Assignee: ISIFER AB
    Inventor: Greta Edelstam
  • Patent number: 9283174
    Abstract: Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base.
    Type: Grant
    Filed: May 10, 2011
    Date of Patent: March 15, 2016
    Inventors: Tatsuya Mori, Naoyuki Saida
  • Patent number: 9242923
    Abstract: Described herein are compositions (e.g., a pharmaceutical composition) and compounds of formula I, and their use in the treatment and/or prevention of diseases and disorders.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: January 26, 2016
    Assignee: CHEMIC LABORATORIES INC.
    Inventors: Joseph P. St. Laurent, Scott A. Goodrich, Gerald S. Jones, Jr.
  • Patent number: 9192572
    Abstract: The present invention provides methods of administering an active agent to a localized mucous membrane in the oral cavity of a mammal, as well as oral dissolving film formed therefore.
    Type: Grant
    Filed: January 1, 2013
    Date of Patent: November 24, 2015
    Inventor: Andrew L. Skigen
  • Patent number: 9138188
    Abstract: Described is a method of treating chronic compartment syndrome in a muscle of a mammal, particularly exertional compartment syndrome. The method includes introducing an effective amount of a nerve-blocking toxin, such as human botulinum toxin into the muscle. In addition to treating chronic or exertional compartment syndrome, a method is included and described of confirming diagnosis of exertional compartment syndrome in a muscle of a mammal. In the method, venous compression and/or expansion in a mammal in an area of a muscle having a symptom associated with exertional compartment syndrome is evaluated by comparing venous flow at rest and after stress on the muscle. An anaesthetic is used to block a nerve supplying motor function to the muscle causing compression of a blood vessel. The mammal is evaluated after the block of the nerve to determine if the symptom associated with exertional compartment syndrome is alleviated.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: September 22, 2015
    Inventor: Joseph C. McGinley
  • Patent number: 9133101
    Abstract: This invention relates to processes for the preparation of (R)-2-acetamido-N-benzyl-3-methoxypropionamide (I) and intermediates thereof. Formula (I).
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: September 15, 2015
    Assignee: Signa S.A. de C.V.
    Inventors: Pablo Miguel Bernal-Vazquez, José Miguel Lazcano-Seres, Yaneth Mariá-Antonieta Contreras-Martinez, Jorge Alberto Juárez-Lagunas, Donato Sánchez-Mereles, Juan Rolando Vázquez-Miranda, Armando Zambrano-Huerta
  • Publication number: 20150148379
    Abstract: The present invention relates to an acetaminophen injectable aqueous solution for use in the treatment or in the prevention of pain by spinal administration, wherein said acetaminophen injectable solution is supersaturated. In certain embodiments, the acetaminophen injectable aqueous solution is administered simultaneously, separately or sequentially with a local anaesthetic by spinal administration.
    Type: Application
    Filed: June 27, 2013
    Publication date: May 28, 2015
    Inventors: Augusto Mitidieri, Elisabetta Donati, Nicola Caronzolo
  • Publication number: 20150133502
    Abstract: The disclosure provides for means for a method to facilitate food intake and food retention in a mammal by applying a sufficient dose of a local anesthetic drug in the lumen of the pharyngeal-esophageal-gastric-duodenal tract before or during or after eating. The local anesthetic can be amethocaine, articaine, benzocaine, bupivacaine, chloroprocaine, cinchocaine, cyclomethycaine, dibucaine, diethocaine, etidocaine, larocaine, levobupivacaine, lidocaine, lignocaine, mepivacaine, novocaine, piperocaine, prilocaine, procaine, proparacaine, propoxycaine, QX-222, QX-314, ropivacaine, tetracaine, trimecaine, menthol, eugenol or a safe pharmaceutical formulations of tetrodotoxin, saxitoxin, or neosaxitoxin. The disclosure is useful for patients having problems with food intake or food retention.
    Type: Application
    Filed: May 15, 2013
    Publication date: May 14, 2015
    Applicant: Chardon Group B.V.
    Inventors: Christophorus Louis Eduard Broekkamp, Bernardus Wijnand Mathijs Marie Peeters
  • Publication number: 20150126481
    Abstract: The present disclosure is drawn to an adhesive peel-forming formulation for dermal delivery of a drug, comprising a drug, a solvent vehicle, and a polymer peel-forming agent. The solvent vehicle can comprise a volatile solvent system comprising one or more volatile solvent, and a non-volatile solvent system comprising two or more non-volatile solvents. The non-volatile solvent system can have a solubility with respect to the drug that is within a window of operable solubility such that the drug is deliverable at therapeutically effective rates over a sustained period of time.
    Type: Application
    Filed: November 5, 2014
    Publication date: May 7, 2015
    Inventors: Jie Zhang, Kevin S. Warner, Michael A. Ashburn, Larry D. Rigby, Suyi Niu
  • Publication number: 20150119467
    Abstract: Methods, systems, devices, and medicaments are provided for locally administering to a pelvic-area organ or tissue structure in a patient at least one drug continuously or continually over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect in another organ or tissue structure by means of shared or convergent pelvic afferent pathways. The methods systems, devices, and medicaments can be used in the treatment of IC/BPS, chronic pelvic pain, vulvodynia, orchialgia, urethral syndrome, dysparenia, chronic prostatitis, chronic pelvic pain, levator ani syndrome, irritative bowel syndrome, or a combination thereof. The drug may include anesthetic agents, analgesic agents, antispasmodic agents, antimuscarinic agents, and combinations thereof. The drug may be released from a drug delivery device or a sustained release composition deployed inside the bladder.
    Type: Application
    Filed: April 30, 2013
    Publication date: April 30, 2015
    Inventors: Julie Himes, Dennis Giesing, Cheryl Larrivee-Elkins, Michael J. Cima, Purnanand Sarma, Paul Goldenheim
  • Publication number: 20150119440
    Abstract: Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 30, 2015
    Inventors: John Scott Karolchyk, Mark L. Baum
  • Publication number: 20150110852
    Abstract: A system for dermal delivery of lidocaine, bupivacaine, diclofenac, or ketoprofen is provided which comprises at least two components, for example, a sheet of a solid and flexible material, and a vehicle liquid comprising a solvent and optionally other ingredients. A drug, selected from group consisting of lidocaine, bupivacaine, diclofenac, and ketoprofen, can be impregnated in the sheet or contained in the vehicle liquid. These two components can be stored separately and joined either shortly before or at the time of application. To use the system, the vehicle liquid may be applied either on the target skin area or on the sheet, and the sheet may then be applied on the target skin area so that the vehicle liquid is positioned between the sheet and the skin and brought into contact with the ingredients impregnated in the sheet.
    Type: Application
    Filed: May 8, 2013
    Publication date: April 23, 2015
    Inventor: Jie Zhang
  • Patent number: 9012477
    Abstract: A method for treating subjects experiencing neuropathic pain is provided. The method involves the application of a solid-forming local anesthetic formulation to a skin surface of the subject experiencing the neuropathic pain and then maintaining the formulation on the skin surface for a period of time sufficient to allow itself to transdermally deliver the local anesthetic to the subject thereby providing relief from the neuropathic pain within about 45 minutes.
    Type: Grant
    Filed: January 5, 2010
    Date of Patent: April 21, 2015
    Assignee: Nuvo Research Inc.
    Inventors: Jie Zhang, Robert Lippert
  • Publication number: 20150105426
    Abstract: The invention relates to novel formulations for topical local anaesthesia and for the use thereof as analgesics, antalgics, or as sexual retardants.
    Type: Application
    Filed: December 4, 2012
    Publication date: April 16, 2015
    Applicant: UNIVERSITE PARIS DESCARTES
    Inventors: Mathieu Lazerges, Philippe Espeau, Sylvie Sophie Crauste-Manciet, Denis Brossard, Yohann Corvis, Florence Agnely, Nicolas Huang
  • Publication number: 20150099015
    Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.
    Type: Application
    Filed: November 24, 2014
    Publication date: April 9, 2015
    Inventor: Guochuan Emil TSAI
  • Publication number: 20150099244
    Abstract: A substance that sets in a relatively short time for use in general dentistry and in endodontics to replace natural tooth material, the substance comprising untreated mineral trioxide aggregate and milled mineral trioxide aggregate, or comprising untreated mineral trioxide aggregate, milled mineral trioxide aggregate and water. A method of making a substance that sets in a relatively short time for use in general dentistry and in endodontics to replace natural tooth material, the method comprising milling by high shear and impact impingement of particles using high pressure homogenization. A method for use in general dentistry and in endodontics to replace natural tooth material.
    Type: Application
    Filed: March 20, 2013
    Publication date: April 9, 2015
    Applicant: LOMA LINDA UNIVERSITY
    Inventors: Mahmoud Torabinejad, Homayoun Moaddel
  • Publication number: 20150087714
    Abstract: The invention features a method for inhibiting one or more voltage-gated ion channels in a cell by contacting the cell with (i) a first compound that activates a channel-forming receptor that is present on nociceptors and/or pruriceptors; and (ii) a second compound that inhibits one or more voltage-gated ion channels when applied to the internal face of the channels but does not substantially inhibit said channels when applied to the external face of the channels, wherein the second compound is capable of entering nociceptors or pruriceptors through the channel-forming receptor when the receptor is activated. The invention also features a quaternary amine derivative or other permanently or transiently charged derivative of a compound that inhibits one or more voltage-gated ion channels when applied to the internal face of the channels but does not substantially inhibit said channels when applied to the external face of the channels.
    Type: Application
    Filed: September 25, 2014
    Publication date: March 26, 2015
    Inventors: Bruce P. BEAN, Clifford J. WOOLF
  • Publication number: 20150065577
    Abstract: The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in ADHD and ADD patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in ADHD and ADD patients. The invention also includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered with one or more other active agents. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.
    Type: Application
    Filed: August 20, 2014
    Publication date: March 5, 2015
    Inventor: Louis Sanfilippo
  • Publication number: 20150056305
    Abstract: Provided are dithiol mucolytic agents. These agents increase the liquefaction of mucus in a patient with excessive mucus or mucus with increased viscoelastic, cohesive, or adhesive properties. Also provided are a variety of methods of treatment using these inventive mucolytic agents.
    Type: Application
    Filed: August 13, 2014
    Publication date: February 26, 2015
    Applicant: PARION SCIENCES, INC.
    Inventors: Michael R. Johnson, William R. Thelin, Ronald A. Aungst, JR.
  • Publication number: 20150045388
    Abstract: A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a drug to the back of the neck of a human patient at the hairline in close proximity to and under or on the area of skin above the brain stem to provide regional neuro-affective therapy is disclosed.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventor: Ronald AUNG-DIN
  • Publication number: 20150045437
    Abstract: Provided are kits containing a base composition and an active pharmaceutical ingredient for transdermal delivery of active pharmaceutical ingredients. Examples of active pharmaceutical ingredients include amitriptyline, baclofen, cyclobenzaprine HCl, ibuprofen, lidocaine HCl, naproxen and tramadol, ketoprofen, diclofenac, phenylbutazone, mefenamic acid, flubiprofen, piroxicam, guaifenasin, prilocaine, bupivicaine, tetracaine, nifedipine, verapamil, orphenadrine, imipramine, ketamine, gabapentin, carbamazepine, menthol, capsaicin, clonidine, dexamethasone, dextromethorphan, testosterone, progesterone, and estrogens.
    Type: Application
    Filed: August 8, 2014
    Publication date: February 12, 2015
    Inventor: Robert Prentice Nickell
  • Publication number: 20150025152
    Abstract: A pharmaceutical formulation for treatment of shingles is provided. The formulation includes between 0.2 mg of menthol per 120 mL of the formulation and 1.0 mg of menthol per 120 mL of the formulation, camphor water, lime water, and a local anesthetic. The local anesthetic includes one of between 0.6 mL of phenol per 120 mL of the formulation and 2.0 mL of phenol per 120 mL of the formulation and between 0.25% concentration by weight of lidocaine and 5% concentration by weight of lidocaine.
    Type: Application
    Filed: July 16, 2014
    Publication date: January 22, 2015
    Inventors: Howard L. Wray, Aman Singh
  • Publication number: 20150017103
    Abstract: The present invention relates to a waterless composition and foam as a vehicle in which an active pharmaceutical or cosmetic agent, when added is stable or stabilized by or its destabilization is impeded by the presence of a modulating agent. The pharmaceutical or cosmetic composition and foam, includes: a waterless solvent, a modulating agent and one or more active pharmaceutical or cosmetic agents. The present invention also relates to a method of treatment administering the waterless composition and foam.
    Type: Application
    Filed: October 3, 2013
    Publication date: January 15, 2015
    Applicant: Foamix Ltd.
    Inventors: Dov Tamarkin, Meir Eini, Doron Friedman, Tal Berman, David Schuz
  • Publication number: 20150018387
    Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit neuropathic pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.
    Type: Application
    Filed: September 11, 2014
    Publication date: January 15, 2015
    Inventors: James N. Campbell, Arthur F. Michaelis
  • Publication number: 20150011640
    Abstract: A gynecologic composition contains spermidine to treat vulvar vestibulitis syndrome (VVS). In this therapeutic context, spermidine is effective at around one micromole per applied dose in the form of a simple salt or complex, alone or in combination or in conjunction with auxiliary actives such as anaesthetics and estrogens.
    Type: Application
    Filed: March 5, 2013
    Publication date: January 8, 2015
    Inventor: Carlo GHISALBERTI
  • Publication number: 20150010638
    Abstract: It is an object of the present invention to provide a method for improving the solubility of a poorly-soluble substance, which is capable of increasing the solubility of substantially all poorly-soluble substances. This is a method comprising coating the surface of a poorly-soluble substance particle with microparticles of a calcium compound such as calcium phosphate or calcium carbonate, and at least one selected from a pH adjuster and a surfactant, by applying mechanical energy thereto.
    Type: Application
    Filed: February 21, 2013
    Publication date: January 8, 2015
    Inventors: Shuji Sakuma, Keiichiro Kikukawa, Ryosuke Miyasaka
  • Publication number: 20150011641
    Abstract: The present invention relates to the field of carrier and delivery systems for active molecular compounds. In particular, the present invention provides aqueous dispersions for delivery of active molecular compounds.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Inventors: Jai Supamahitorn, Lauren McMillan
  • Patent number: 8927608
    Abstract: A formulation comprising dexamphetamine and lys-dexamphetamine useful in the treatment of ADHD or fatigue.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: January 6, 2015
    Assignee: Jagotec AG
    Inventors: Guy Vergnault, Pascal Grenier
  • Patent number: 8927010
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: January 6, 2015
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Publication number: 20150004206
    Abstract: The invention relates to a process for preparing PCL-comprising microparticles, to microparticles obtainable by said process, to gel hence obtained and to several uses of the gel such as for the preparation of a medicament for treating a skin abnormality or disfigurement, and/or for controlling bladder function and/or controlling gastric reflux and/or for treating erectile dysfunction and/or for treating vocal cords. The gel may also be used for cosmetic applications.
    Type: Application
    Filed: July 1, 2014
    Publication date: January 1, 2015
    Inventors: Henderikus Supèr, Paul Willem Mijnen, Pieter Gerard Zijlstra, Dirk Wybe Grijpma
  • Publication number: 20150005328
    Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.
    Type: Application
    Filed: July 2, 2014
    Publication date: January 1, 2015
    Inventors: Stanton F. MCHARDY, Richard M. CORBETT, Donald M. MAXWELL, Michael W. TIDWELL, Bismarck CAMPOS, Christopher J. BEMBEN
  • Patent number: 8920831
    Abstract: A lidocaine-containing hydrogel patch comprising: a support layer; and a adhesive layer stacked on a surface of the support layer, wherein the adhesive layer comprises at least one selected from the group consisting of lidocaine and pharmaceutically acceptable salts thereof, a total content of the lidocaine and the pharmaceutically acceptable salts thereof is 3 to 8% by mass relative to an entire mass of the adhesive layer, the adhesive layer further comprises oleic acid in an amount of 0.3 to 1% by mass relative to the entire mass of the adhesive layer, and a pH of the adhesive layer is 6.8 to 7.4.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: December 30, 2014
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Junichi Kubo, Seiichiro Tsuru, Keiichiro Tsurushima, Shinji Yamasoto
  • Publication number: 20140378549
    Abstract: A composition of matter and method for preparation of a tissue augmentation material. A polysaccharide gel composition is prepared with rheological properties selected for a particular selected application. The method includes preparing a polymeric polysaccharide in a buffer to create a polymer solution or gel suspending properties in the gel and selecting a rheology profile for the desired tissue region.
    Type: Application
    Filed: May 5, 2014
    Publication date: December 25, 2014
    Applicant: MERZ NORTH AMERICA, INC.
    Inventors: Robert VOIGTS, Dale DEVORE
  • Patent number: 8916588
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: December 23, 2014
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 8911765
    Abstract: A biodegradable, flexible covering for a breast implant is provided which comprises one or more biodegradable polymer layers dimensioned and shaped to cover at least a portion of the breast implant. The implant can be inserted into an opening of the covering immediately prior to surgery, but alternate configurations and times of insertion are contemplated as well as open or sheet type devices. The coverings can optionally contain one or more drugs for delivery at the surgical site, particularly for treating or preventing infection, pain, inflammation, capsular contracture, scarring or other complications associated with breast augmentation or breast reconstruction.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: December 16, 2014
    Assignee: Tyrx, Inc.
    Inventors: Arikha Moses, Satish Pulapura, Qing Ge, Sarita Nethula, Irene Shatova, Archana Rajaram
  • Patent number: 8906919
    Abstract: The present invention relates to a method for slowing the development of mammalian organ, tissue and cellular damage and death by using a persistent sodium current blocker (or a pharmaceutically acceptable salt or derivative thereof). The present invention further relates to a method for preventing damage and death in mammalian organs, tissues and cells or reducing the extent of damage and death in mammalian organs, tissues and cells. In particular the invention relates to a method for the treatment, amelioration or prevention of non-neuronal and non-myocardial cell or tissue damage or death and for reducing the pain associated with non-neuronal and non-myocardial cell or tissue damage.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: December 9, 2014
    Assignee: Ozteo Pty Ltd
    Inventors: Paul Nathaniel Smith, Steven Michael Weiss
  • Publication number: 20140356412
    Abstract: [Problem] If lidocaine is composed of non-aqueous patch, the adhesive power of the preparation tends to get lower, as the composition amount of lidocaine is higher. It is popular to solve lidocaine in dissolving agent in order to compose lidocaine in patch and release effective amount into skin. However, if the amount of dissolving agent gets higher, the adhesive power gets extremely lower, so that an long-time attachment is difficult. [Solution] A non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent which are contained in a base of plaster, the plaster being hold by a support, of which strength of 50% stretched to longitudinal direction is less than 2,000 g/50 mm and of biaxially-oriented stretch cloth.
    Type: Application
    Filed: September 27, 2011
    Publication date: December 4, 2014
    Applicants: OISHI KOSEIDO CO., LTD., ITOCHU CHEMICAL FRONTIER CORPORATION
    Inventors: Tatsuya Mori, Naoyuki Saida
  • Publication number: 20140357600
    Abstract: Described herein are compositions (e.g., a pharmaceutical composition) and methods for controlling the delivery of a therapeutic agent, and their use in the treatment and/or prevention of diseases and disorders.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 4, 2014
    Applicant: CHEMIC LABORATORIES INC.
    Inventors: Joseph P. St. Laurent, Scott A. Goodrich, Gerald S. Jones, Jr.
  • Publication number: 20140350097
    Abstract: There is provided a method for the prevention and/or treatment of hypotension associated with hemodialysis, which method includes administering to a subject in need thereof an effective amount of at least one physiologically compatible compound which, in combination with iron, binds nitric oxide. There is further provided a method for identifying hemodialysis subjects for whom treatment with an effective amount of at least one physiologically compatible compound which, in combination with iron, binds nitric oxide is indicated. The method includes monitoring the subject's nitric oxide levels, and selecting those subjects having elevated nitric oxide levels for treatment with an effective amount of at least one physiologically compatible compound which, in combination with iron, binds nitric oxide, wherein the effective amount is sufficient to maintain the subject's nitric oxide levels within an acceptable range.
    Type: Application
    Filed: May 23, 2013
    Publication date: November 27, 2014
    Applicant: Medinox,Inc.
    Inventor: Ching-San Lai
  • Publication number: 20140348959
    Abstract: Compositions and methods for treatment of conditions such as ear pain are disclosed.
    Type: Application
    Filed: August 12, 2014
    Publication date: November 27, 2014
    Inventors: Mark A. Mitchnick, Garry Gwozdz
  • Publication number: 20140343067
    Abstract: The present invention relates to a method of reducing cutaneous facial flushing caused by systemic use of phosphodiesterase type 5 (PDE5) inhibitors by topical facial dermatological application of an effective dose of a composition comprising at least one alpha adrenergic receptor agonist.
    Type: Application
    Filed: October 12, 2012
    Publication date: November 20, 2014
    Inventors: Warren J. Scherer, Arthur Clapp, Philippe Andres
  • Publication number: 20140335206
    Abstract: This invention concerns a synergistic combination of a topical anesthetic and wound barrier forming agent capable of providing extended analgesia of ‘significant open wounds’ (that being, for example, a laceration, surgical incision, abrasion, ulcer or burn, but not being a minor cut, scratch, sting, burn or abrasion) in which conventional management alternatives (such as suturing and/or administration of injected or systemic analgesia) are impractical, unaffordable or otherwise unavailable.
    Type: Application
    Filed: July 25, 2014
    Publication date: November 13, 2014
    Inventors: Meridith Sheil, Allan Giffard, Charles R. Olsson
  • Publication number: 20140329906
    Abstract: The present invention relates to a thermogelling pharmaceutical composition comprising local anaesthetics in base form and which is suitable for topical administration. The compositions further comprise a polyoxyethylene castor oil and one or more surfactants to obtain thermogelling characteristics.
    Type: Application
    Filed: July 18, 2014
    Publication date: November 6, 2014
    Inventors: Mark Sundberg, Arne Brodin, Nils Kallberg
  • Publication number: 20140322330
    Abstract: The present invention relates to methods of forming miniemulsions and use of the miniemulsions as a delivery system for bioactive agents. In particular, the present invention relates to methods for forming a miniemulsion comprising providing a first phase comprising a hydrophilic surfactant, lipophillic surfactant and water and a second phase comprising a lipid, wherein said miniemulsion comprises emulsified particles having a mean diameter of 1 ?m or less.
    Type: Application
    Filed: December 9, 2011
    Publication date: October 30, 2014
    Applicant: NS TECHNOLOGIES PTY LTD
    Inventor: Desai Chiragkumar
  • Publication number: 20140323578
    Abstract: A composition is disclosed. The composition comprises at least one polymeric colorant having a polymer component with a colorant component covalently bound thereto, a medicament, and a liquid vehicle. The at least one colorant component does not react directly or indirectly with the medicament. Methods of using the polymeric colorants, including a method for the preparation of skin as a site for a surgical procedure and a method of treating a medical condition, are also provided.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 30, 2014
    Inventors: Louis C. Haddad, Douglas A. Hanggi, David B. Olson, Matthew T. Scholz, Dong-Wei Zhu
  • Publication number: 20140323577
    Abstract: This invention relates to a method for reducing the risk of conversion to clinically definite multiple sclerosis (CDMS) in patients who have experienced their first neurological symptoms consistent with clinically isolated syndrome (CIS).
    Type: Application
    Filed: April 24, 2014
    Publication date: October 30, 2014
    Applicant: Sanofi-Aventis U.S. LLC
    Inventor: Barbara WAMIL